Moderna says more than 40% of participants enrolled for COVID-19 vaccine trial

imageCoronavirus39 minutes ago (Aug 21, 2020 09:45PM ET)

(C) Reuters. FILE PHOTO: Moderna Therapeutics seen during COVID-19 in Massachusetts

(Reuters) – Drug developer Moderna (NASDAQ:MRNA) Inc on Friday said it has so far enrolled 13,194 participants in the ongoing late-stage 30,000-volunteer U.S. trial testing its COVID-19 vaccine candidate.

In a tweet, the company also said that 18% of the participants currently enrolled are Black, Latino, American Indian or Alaska Native, groups among the hardest hit by the coronavirus virus pandemic.

Moderna began the study of its vaccine candidate, mRNA-1273, in July and expects to complete enrollment in September. The 30,000 subject U.S. trial is among the first late-stage studies supported by the Trump administration’s effort to speed development of measures against the novel coronavirus, adding to hope that an effective vaccine will help end the pandemic.

Last week, the company entered a supply agreement with the U.S. government to provide 100 million doses of its potential COVID-19 vaccine for around $1.5 billion.

Moderna, which has never brought a vaccine to market, had earlier received nearly $1 billion from the U.S. government, which is helping bankroll several vaccine candidates under its Operation Warp Speed program.

Black and Latino Americans are infected with COVID-19 at more than twice the rate of white Americans, with Native Americans infected at even higher rates, research has shown. The groups are historically underrepresented in clinical trials.

A top executive of Pfizer (NYSE:PFE) told Reuters that about 19% of the 11,000 people enrolled so far in a 30,000-volunteer U.S. trial of its COVID-19 vaccine with German partner BioNTech are Black or Latino.

Moderna says more than 40% of participants enrolled for COVID-19 vaccine trial

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.